Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review

Vaccine
Volume 31, Issue 37, Pages 3763-4054 (20 August 2013)
http://www.sciencedirect.com/science/journal/0264410X/31/37

Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review
Review Article
Pages 3786-3804
Michaela Fesenfeld, Raymond Hutubessy, Mark Jit

Abstract
The World Health Organization recommends establishing that human papillomavirus vaccination is cost-effective before vaccine introduction. We searched Pubmed, Embase and the Cochrane Library to 1 April 2012 for economic evaluations of human papillomavirus vaccination in low and middle income countries. We found 25 articles, but almost all low income countries and many middle income countries lacked country-specific studies. Methods, assumptions and consequently results varied widely, even for studies conducted for the same country. Despite the heterogeneity, most studies conclude that vaccination is likely to be cost-effective and possibly even cost saving, particularly in settings without organized cervical screening programmes. However, study uncertainty could be reduced by clarity about vaccine prices and vaccine delivery costs. The review supports extending vaccination to low income settings where vaccine prices are competitive, donor funding is available, cervical cancer burden is high and screening options are limited.